Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC by Ballas, Marc S & Chachoua, Abraham
© 2011 Ballas and Chachoua, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2011:4 43–58
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
43
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OTT.S18155
Rationale for targeting veGF, FGF, and PDGF  
for the treatment of NSCLC
Marc S Ballas1
Abraham Chachoua2
1Department of Medicine (Cancer 
Center), New York University Langone 
School of Medicine, New York, NY, 
USA; 2Department of Cardiothoracic 
Surgery, New York University Langone 
School of Medicine, New York, NY, USA
Correspondence: Marc S Ballas 
New York University Langone School  
of Medicine, 160 east 34th Street,  
Room 820, New York, NY 10016, USA 
Tel +1 212 731 6645 
Fax +1 212 731 5545 
email marcballas@gmail.com
Abstract: Lung cancer remains a leading cause of death globally, with the most frequent type, 
nonsmall cell lung cancer (NSCLC), having a 5-year survival rate of less than 20%. While 
platinum-based doublet chemotherapy is currently first-line therapy for advanced disease, it 
is associated with only modest clinical benefits at the cost of significant toxicities. In an effort 
to overcome these limitations, recent research has focused on targeted therapies, with recently 
approved agents targeting the epidermal growth factor receptor and vascular endothelial growth 
factor (VEGF) signaling pathways. However, these agents (gefitinib, erlotinib, and bevacizumab) 
provide antitumor activity for only a small proportion of patients, and patients whose tumors 
respond inevitably develop resistance to treatment. As angiogenesis is a crucial step in tumor 
growth and metastasis, antiangiogenic treatments might be expected to have antitumor   activity. 
Important targets for the development of novel antiangiogenic therapies include VEGF, fibroblast 
growth factor, platelet-derived growth factor, and their receptors. It is hypothesized that target-
ing multiple angiogenic pathways may not only improve antitumor activity but also reduce the 
risk of resistance. Several novel agents, such as BIBF 1120, sorafenib, sunitinib, and cediranib 
have shown promising preliminary activity and tolerability in Phase II studies, and results of 
ongoing Phase III randomized studies will be necessary to establish the potential place of these 
new therapies in the management of individual patients with NSCLC.
Keywords: angiogenesis, vascular endothelial growth factor, platelet-derived growth factor, 
fibroblast growth factor, tyrosine kinase inhibitor, nonsmall cell lung cancer
Introduction
Lung cancer is the leading cause of cancer-related death worldwide.1 Nonsmall cell 
lung cancer (NSCLC) is the most frequent type of lung cancer, accounting for more 
than 80% of lung cancer cases. As NSCLC currently has a 5-year survival rate of less 
than 20%,2 there is clearly a need for the development of more effective therapies.
Standard first-line treatment options depend on disease and patient characteris-
tics, and may include surgery, platinum-based doublet chemotherapy, and targeted 
  therapies.3 However, surgical resection is only a curative option if diagnosis occurs at 
early stage I or stage II disease (Table 1). At times, surgery with or without radiation 
with a more limited curative potential is an option for selected stage III NSCLC patients. 
Chemotherapy with a platinum-based doublet regimen is currently first-line therapy 
for more advanced disease, but is associated with only modest clinical benefits at the 
cost of significant toxicities.4,5 Furthermore, studies have shown no survival benefit 
and decreased quality of life with chemotherapy combinations beyond 4–6 cycles.6–8 
Thus, in an effort to overcome these limitations, recent research has focused on targeted OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Staging of NSCLCa
Stage TNMb Description
Occult carcinoma Tx 
N0 
M0
Tumor that cannot be assessed or detected radiologically  
or bronchoscopically but is proven histopathologically 
No regional node involvement 
No distant metastases
0 Tis 
N0 
M0
Carcinoma in situ 
No regional node involvement 
No distant metastases
iA T1a 
T1b 
N0 
M0
Tumor #2 cm surrounded by lung or visceral pleura and involving  
lobar bronchus but not main bronchus 
Tumor .2 cm but #3 cm surrounded by lung or visceral pleura  
and involving lobar bronchus but not main bronchus 
No regional node involvement 
No distant metastases
iB T2a 
N0 
M0
Tumor .3 cm but #5 cm involving main bronchus $2 cm from carina  
or presence of atelectasis or obstructive pneumonitis that extends to  
the hilar region and involving invading visceral pleura 
No regional node involvement 
No distant metastases
iiA T1a 
T1b 
N1 
M0 
Or 
T2a 
N1 
M0 
Or 
T2b 
N0 
M0
Tumor #2 cm surrounded by lung or visceral pleura and involving lobar bronchus  
but not main bronchus 
Tumor .2 cm but #3 cm surrounded by lung or visceral pleura and involving lobar   
bronchus but not main bronchus 
involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes 
No distant metastases
Tumor .3 cm but #5 cm involving main bronchus $2 cm from carina or  
presence of atelectasis or obstructive pneumonitis that extends to the hilar  
region and involving invading visceral pleura 
involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes 
No distant metastases 
Tumor .5 cm but #7 cm involving main bronchus $2 cm from carina or  
presence of atelectasis or obstructive pneumonitis that extends to the hilar  
region and involving invading visceral pleura 
No regional node involvement 
No distant metastases
iiB T2b 
N1 
M0 
Or 
T3 
N0 
M0
Tumor .5 cm but #7 cm involving main bronchus $2 cm from carina or  
presence of atelectasis or obstructive pneumonitis that extends to the hilar  
region and involving invading visceral pleura 
involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes 
No distant metastases 
Tumor .7 cm involving main bronchus ,2 cm from carina or presence of  
atelectasis or obstructive pneumonitis of the entire lung and involving direct  
invasion of chest wall, diaphragm, phrenic nerve, mediastinal pleura, or parietal  
pericardium and involving satellite tumor nodule(s) in same lobe as primary tumor 
No regional node involvement 
No distant metastases
iiiA T1–T3 
N2 
M0 
Or 
T3 
N1
involvement of ipsilateral mediastinal or subcarinal nodes 
No distant metastases 
Tumor .7 cm involving main bronchus ,2 cm from carina or presence of  
atelectasis or obstructive pneumonitis of the entire lung and involving direct  
invasion of chest wall, diaphragm, phrenic nerve, mediastinal pleura, or parietal  
pericardium and involving satellite tumor nodule(s) in same lobe as primary tumor 
involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes
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Table 1 (Continued)
Stage TNMb Description
M0
Or 
T4 
N0–N1 
M0
No distant metastases
Tumor any size invading the mediastinum, heart, great vessels, trachea, recurrent 
laryngeal nerve, esophagus, vertebral body, or carina; or tumor with satellite tumor 
nodule(s) in a different lobe, ipsilateral to that of the primary tumor 
No regional node involvement or involvement of ipsilateral peribronchial or hilar  
nodes and intrapulmonary nodes 
No distant metastases
iiiB T1–T4 
N3 
M0 
Or 
T4 
N2 
M0
involvement of contralateral mediastinal or hilar nodes and ipsilateral or  
contralateral scalene or supraclavicular nodes 
No distant metastases 
Tumor any size invading the mediastinum, heart, great vessels, trachea, recurrent  
laryngeal nerve, esophagus, vertebral body, or carina; or tumor with satellite  
tumor nodule(s) in a different lobe, ipsilateral to that of the primary tumor 
involvement of ipsilateral mediastinal or subcarinal nodes 
No distant metastases
iv Tx–T4 
Nx–N3c 
M1a 
M1b
Any T 
Any N 
Satellite tumor nodule(s) in contralateral lobe to that of primary tumor or tumors 
with malignant pleural or pericardial effusion 
Distant metastases
Notes: aBased on the Seventh edition of TNM Staging of Lung Tumors; however, trials referred to in this review article have followed either the current or previous staging 
system depending on the time of their conduct; bThe TNM system is based on tumor status, nodal status, and metastatic disease; cNx indicates regional lymph nodes that 
cannot be assessed. 
Copyright © 2011. Adapted with permission from the American College of Chest Physicians. Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual   
and stage grouping of lung cancer: quick reference chart and diagrams. Chest. 2011;139(1):183–189.114 
Abbreviations: NSCLC, nonsmall cell lung cancer; TNM, tumor node metastasis.
therapies that may more selectively inhibit tumor cell growth 
while minimizing toxicity to healthy cells and tissue.
Currently available targeted  
agents for NSCLC
Currently approved targeted agents in NSCLC are limited to 
inhibition of the epidermal growth factor receptor (EGFR)9,10 
and vascular endothelial growth factor (VEGF) signaling 
  pathways.11 The EGFR family of receptor tyrosine kinases 
serve as mediators of cell signaling by extracellular growth 
factors, with binding of their ligands activating intracellular 
pathways that promote tumor growth and survival.12 An acti-
vating mutation in EGFR is observed in approximately 10% 
of unselected Western lung cancer patients and in a higher per-
centage of certain NSCLC subgroups, such as nonsmokers and 
those of Asian ethnicity.12 Reversible EGFR-targeting tyrosine 
kinase inhibitors such as gefitinib (Iressa®;   AstraZeneca; 
Wilmington, DE) and erlotinib (Tarceva®; Genentech; South 
San Francisco, CA) inhibit EGFR signaling.
Initial Phase II results with gefitinib led to approval by 
the United States Food and Drug Administration (FDA) of 
this agent for NSCLC. These results showed overall objective 
response rates (ORR) of 19% (95% confidence interval [CI], 
11.5–27.3) among 105 patients with stage III/IV NSCLC 
receiving a dose of 500 mg/day and 18.4% (95% CI, 
12.1–27.9) of 103 patients receiving 250 mg/day in one 
study and 10.6% (95% CI, 6.0–16.8) with both doses in 
another study.13,14 However, addition of gefitinib to   standard 
chemotherapy failed to prolong overall survival (OS) com-
pared with chemotherapy alone in subsequent Phase III 
trials.15–17 Based on more recent Phase III data in which OS 
with gefitinib was noninferior or not significantly different 
to that obtained with docetaxel, a taxane,18 in patients with 
advanced or metastatic NSCLC who had been pretreated 
with platinum-based chemotherapy,19,20 the United States 
restricted treatment with gefitinib to patients who have previ-
ously benefited from it.10 However, in the European Union 
and Asia, gefitinib remains in use for NSCLC patients with 
EGFR-activating mutations.21
Erlotinib was approved in the United States in 2004 for 
the treatment of patients with locally advanced or metastatic 
NSCLC whose disease has progressed following at least one 
chemotherapy regimen3,22 based on prolongation of OS (6.7 
versus 4.7 months for placebo; hazard ratio (HR), 0.70; 95% 
CI, 0.58–0.85; P , 0.001) in a double-blind Phase III trial, 
BR21, involving 731 patients with stage IIIB/IV NSCLC.23 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Erlotinib was also recently approved for maintenance therapy 
in patients with locally advanced or metastatic NSCLC whose 
disease has not progressed after 4 cycles of platinum-based 
therapy,24 based on the SATURN trial. The SATURN Phase 
III trial (N = 884) showed erlotinib prolonged progression-
free survival (PFS) versus placebo irrespective of EGFR 
mutation status (12.3 versus 11.1 weeks; HR, 0.71; 95% CI, 
0.62–0.82; P , 0.0001).25
Response rates in the gefitinib and erlotinib Phase III stud-
ies that were conducted in nonselected populations were typi-
cally around 10%, meaning that for many patients, their tumors 
fail to respond to these agents.26–28 Those who do respond to 
treatment eventually develop resistance to EGFR tyrosine 
kinase inhibitors, due either to a secondary mutation in the 
EGFR gene or amplification of mesenchymal-epithelial transi-
tion factor (MET), another receptor tyrosine kinase.12,29
The VEGF pathway controls angiogenesis, a necessary step 
in tumor growth, metastasis, and malignancy.30   Formation of 
new vasculature is required for larger tumors to obtain nutrients 
and oxygen; otherwise, nutrient supply is limited by diffusion, 
slowing tumor growth.31 Indeed, tumor vascularization is a 
prognostic indicator of disease progression in various cancers, 
including NSCLC.32–34 Thus, as tumor growth is dependent on 
developing and maintaining this blood supply, antiangiogenic 
treatments might be expected to have antitumor activity.
Bevacizumab (Avastin®, Genentech) is a monoclonal 
antibody directed against VEGF that is currently approved 
in combination with carboplatin, a platinum agent, and 
paclitaxel, a taxane, as first-line treatment of unresected, 
locally advanced, recurrent or metastatic nonsquamous 
NSCLC.35 Bevacizumab is only available for patients 
whose tumors have nonsquamous histology and is not 
recommended for patients with hemorrhage or recent 
hemoptysis.11,36,37 These exclusions are based on evidence 
from Phase II and III clinical trials. An early Phase II study 
randomized 99 patients with advanced (stage IIIB/IV or 
recurrent) NSCLC to receive bevacizumab 7.5 mg/kg or 
15 mg/kg plus carboplatin and paclitaxel or chemotherapy 
alone.36 Bevacizumab 15 mg/kg significantly prolonged 
time to disease progression (TTP) (7.4 versus 4.2 months 
with chemotherapy alone; HR, 0.57; P = 0.023) and pro-
vided a higher response rate (31.5% of 34 patients versus 
18.8% of 32 patients) and a modestly increased median OS 
(17.7 versus 14.9 months; P = 0.63). With the lower dose 
of bevacizumab, TTP was 4.3 months, ORR was 28.1% 
of 32 patients, and OS was 11.6 months. However, fatal 
hemoptysis was observed in 4 of 66 patients (6%) receiving 
bevacizumab. The study also correlated squamous histology 
with an increased risk of serious pulmonary hemorrhage, as 
four out of six cases of life-threatening bleeding occurred 
in patients with squamous carcinomas.36
The Phase III Eastern Cooperative Oncology Group (ECOG) 
4599 trial38 evaluated bevacizumab 15 mg/kg in combination 
with carboplatin and paclitaxel in 878 chemotherapy-naive 
patients. Patients with squamous histology, brain metastases, 
inadequate organ function, clinically significant hemoptysis, 
or ECOG performance status .1 were excluded. The ORR 
was higher with bevacizumab (133 out of 381 patients, 35%) 
compared with carboplatin and paclitaxel alone (59 out of 
392 patients, 15%; P , 0.001). The addition of bevacizumab 
also prolonged median OS (12.3 versus 10.3 months; HR, 
0.80; P = 0.003) and PFS (6.2 versus 4.5 months; HR, 0.66; 
P , 0.001) compared with chemotherapy alone. Grade $3 
(lowest possible grade of an adverse event is 1 [mild adverse 
event] and highest possible grade is 5 [death]) bleeding events 
were reported in 19 out of 427 patients receiving bevacizumab 
plus chemotherapy (4.4%), while eight patients (1.9%) expe-
rienced hemoptysis.38 Fifteen treatment-related deaths were 
observed in the bevacizumab arm compared with two deaths 
in the carboplatin plus paclitaxel alone arm (P , 0.001), five of 
which were caused by hemorrhage. Evaluable patients receiv-
ing bevacizumab plus carboplatin and paclitaxel (n = 427) 
experienced higher rates of grade 4 neutropenia (25.5% versus 
16.8% in 440 patients receiving carboplatin and paclitaxel 
alone; P = 0.002) and thrombocytopenia (1.6% versus 0.2%; 
P = 0.04) as well as grade 3 febrile neutropenia (4% versus 
1.8%; P = 0.02), grade 3–4 hyponatremia (3.5% versus 
1.1%; P = 0.02), grade 3–4 hypertension (6.8% versus 0.5%; 
P , 0.001), grade 3 headache (0.5% versus 3%; P = 0.003), 
grade 3 rash (2.3% versus 0.5%; P = 0.02), and grade $3 
bleeding events (0.7% versus 4.4%; P , 0.001).38
In the similarly designed Phase III AVAiL trial, first-line 
treatment with bevacizumab 7.5 or 15 mg/kg in combina-
tion with cisplatin and gemcitabine versus cisplatin and 
gemcitabine alone was evaluated in 1043 patients with 
recurrent or advanced NSCLC.39 Bevacizumab prolonged 
PFS at both 7.5 mg/kg (6.7 versus 6.1 months for placebo; 
HR, 0.75; P = 0.003) and 15 mg/kg (6.5 months; HR, 0.82; 
P = 0.03 versus placebo),39 but OS was not significantly 
different, possibly due to the high use of post-study second-
line treatments.40 The incidence of pulmonary hemorrhage 
was only 1.5% with bevacizumab 7.5 mg/day (5 out of 330 
patients) and 0.9% with bevacizumab 15 mg/kg (3 out of 329 
patients).39 The rates of grade $3 hypertension, vomiting, 
neutropenia, and bleeding were numerically higher in patients 
who received bevacizumab than in patients who did not.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Another Phase III trial, the ATLAS study, compared 
bevacizumab 15 mg/kg plus erlotinib with bevacizumab 
alone as a maintenance therapy after 4 cycles of combined 
treatment with bevacizumab and platinum-based doublet 
chemotherapy in 768 patients with advanced NSCLC.41 
Patients with treated brain metastases and peripheral or 
extrathoracic squamous tumors were allowed to participate 
in this study. Preliminary efficacy results showed that the 
combination of erlotinib plus bevacizumab increased PFS 
(4.8 versus 3.7 months for bevacizumab alone; HR, 0.72; 
95% CI, 0.59–0.88; P = 0.0012) but did not significantly 
prolong OS (15.9 versus 13.9 months; HR, 0.90; P = 0.2686). 
Safety data (n = 598) have been reported for the initial che-
motherapy phase of the trial.42 The most common grade $3 
adverse event was hypertension, reported for 13 out of 303 
patients receiving bevacizumab with carboplatin and pacli-
taxel (4.3%), 9 out of 183 patients receiving bevacizumab 
with carboplatin and gemcitabine (4.9%), and 3 out of 112 
receiving carboplatin plus docetaxel (2.7%). Grade $2 pul-
monary or central nervous system hemorrhage each occurred 
in less than 2% of patients, as did grade $3 gastrointestinal 
  perforations. Overall hemorrhage rates (all grades) were 
reported for seven patients (2.3%) with bevacizumab plus 
carboplatin and paclitaxel, nine patients (4.9%) with beva-
cizumab plus carboplatin and gemcitabine, and nine patients 
(8%) with carboplatin plus docetaxel.
The Phase II BRIDGE study examined whether 
paclitaxel and carboplatin in combination with delayed 
bevacizumab administration would improve tolerability in 
patients with previously untreated squamous NSCLC; out 
of 31 patients treated with bevacizumab, one patient (3.2%) 
experienced a grade 3 pulmonary hemorrhage.43 Ongoing 
follow-up Phase II and III trials are currently evaluating 
bevacizumab therapy in combination with other targeted 
agents as well as standard chemotherapy in both first-line 
and second-line settings for multiple malignancies, includ-
ing NSCLC.40,44–47 While bevacizumab is the only antian-
giogenic therapy currently approved for NSCLC, there are 
several other compounds currently in clinical development, 
including monoclonal antibodies to VEGF and inhibitors 
of the intracellular tyrosine kinase domain of the VEGF 
receptor, as described later in this review. Because of the 
issues of resistance and eligibility associated with currently 
approved targeted agents in NSCLC, there is a critical need 
for improved therapies. The subsequent sections of this 
review highlight important antiangiogenic targets as well 
as emerging clinical data regarding novel antiangiogenic 
compounds for NSCLC treatment.
Rationale for targeting angiogenic 
pathways in NSCLC
veGF signaling
Important proangiogenic targets for the development of 
antiangiogenic therapies include VEGF, fibroblast growth 
factor (FGF), and platelet-derived growth factor (PDGF), 
along with their corresponding receptors (VEGFR, FGFR, 
and PDGFR, respectively). The VEGF-related family 
of proangiogenic signaling factors comprises VEGF-A 
  (commonly referred to as VEGF), VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, and placental growth factor (PlGF).48 
In addition to tumor angiogenesis, VEGF signaling medi-
ates several other pathological conditions including inflam-
matory disorders, female reproductive processes, and 
intraocular neovascularization syndromes.49 The VEGF 
ligands mediate their angiogenic effects via three receptor 
tyrosine kinases: VEGFR-1 (also known as fms-like tyrosine 
kinase 1 [flt-1]), VEGFR-2 (also known as kinase-insert 
domain receptor [KDR]), and VEGFR-3 (flt-4). The primary 
receptor for VEGF is VEGFR-2.49   Binding of VEGF to its 
receptors causes receptor dimerization, autophosphorylation, 
and downstream signaling through a variety of pathways, 
including phosphoinositide (PI)-3 kinase (PI3K), v-src sar-
coma viral oncogene homolog (Src), and phospholipase-Cγ 
(PLCγ), which can activate proliferation and migratory path-
ways driving angiogenesis (Figure 1).49 Neuropilin-1 and 
neuropilin-2, members of the neuropilin family of receptors, 
are expressed on endothelial cells and may be activated by 
VEGF, dimerize with VEGFR-1 and -2, and activate down-
stream signaling;50 inhibitors of neuropilin-VEGF interac-
tion are undergoing preclinical evaluation for the treatment 
of cancer.51,52 In animal tumor models, VEGF is produced 
both by tumor cells and also by stromal tissue,53,54 although 
stromal expression of VEGF was not observed in a study 
of NSCLC samples from patients.55 Upregulation of VEGF 
and VEGFR have been observed in NSCLC tumor samples, 
with expression correlated with tumor angiogenesis, shorter 
postoperative recurrence time, and shorter survival time.55 
A meta-analysis of NSCLC studies has also suggested that 
VEGF expression is an unfavorable prognostic factor for 
survival (HR, 1.48; 95% CI, 1.27–1.72).56
FGF signaling
The FGF family comprises 22 ligands that have a diverse 
array of biological functions. For example, FGF signaling 
plays a role in fetal development; mutations in FGFR1 are 
associated with bone disorders, and mutations in FGFR2 
are known to cause various craniosynostosis syndromes OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48
Ballas and Chachoua
Ras
Raf
PIP2
PIP3
PIP2
IP3
Ca2+
DAG +
PKC
MEK
eNOS
cPLA
Caspase 9 BAD
Akt
HSP27
PI3K p38 FAK
paxillin MAPKAPK 2 and 3
Cell
survival
Cell
migration
Vascular cell
permeability Cell proliferation
Angiogenesis
NOS Prostaglandin
production
Actin
reorganization
Focal adhesion
turnover
ERK
PLC-γ
TKIs
mAbs,
aflibercept
VEGFR
VEGF
mAbs
Extracellular
matrix
TK
Cytoplasm
P
P P
P
Gene expression
Figure 1 Connections between veGF/veGFR signaling and angiogenic processes. Depiction of the role of veGFR signaling in tumor angiogenesis.
Adapted by permission from MacMillan Publishers Ltd: Nat Rev Clin Oncol,113 copyright 2009.
Abbreviations: Akt, protein kinase B; BAD, Bcl-2–associated death promoter; cPLA, cytoplasmic phospholipase A; DAG, diacyl-glycerol; eNOS, endothelial nitric oxide synthase; 
eRK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; HSP, heat shock protein; iP3, inositol trisphosphate; mAbs, monoclonal antibodies; MAPKAPK, mitogen-activated 
protein kinase-actived protein kinase; MeK, mitogen-activated protein kinase kinase; NOS, nitrous oxide synthase; Pi3K, phosphatidylinositol 3-kinase; PiP2, phosphatidylinositol 4,5-
bisphosphate; PiP3, phosphatidylinositol 3,4,5-trisphosphate; PKC, protein kinase C; PLC, phospholipase C; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; Ras, retrovirus-
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  (premature closure of sutures in the fetal skull before 
  completion of brain growth).57 FGF-1, FGF-2, FGF-4, FGF-5, 
and FGF-8 have been associated with angiogenesis.58 Two 
FGF receptor tyrosine kinases, FGFR-1 and FGFR-2, are 
expressed in endothelial cells and can activate signaling 
pathways involved in tumor angiogenesis including the PI3K 
and mitogen-activated protein kinase (MEK)–  extracellular 
signal-regulated kinase kinase (ERK) pathways,58 resulting 
in endothelial cell activation and recruitment of pericytes, 
vascular smooth muscle cells, and monocytes.58,59 FGF also 
regulates expression of proteases, integrins, and cadherins 
involved in reorganization of the extracellular matrix.60,61 
In this way, FGF signaling affects vascular integrity, an 
important component of the vascular remodeling required 
for angiogenesis.62 In addition, cross-talk between FGFs, 
VEGFs, and inflammatory cytokines and chemokines may 
play a role in the modulation of blood vessel growth in vari-
ous pathological conditions, including tumors.58
PDGF signaling
PDGF ligands are released from platelets upon vas-
cular damage.63 There are five dimeric PDGF ligands, 
PDGF-AA, -BB, -CC, -DD, and -AB, and two receptor 
tyrosine kinases, PDGFR-α and PDGFR-β, which mediate 
downstream effects through some of the same pathways acti-
vated by VEGFR (Figure 1).64 These receptors are expressed 
on endothelial cells, pericytes, and vascular smooth muscle 
cells,63 which aid in development of tumor microvessels. 
Release of PDGF-BB by endothelial cells recruits pericytes 
and vascular muscle cells, which, in turn, control vascular 
integrity, development, and stabilization.65–67 In a preclinical 
chorioallantoic membrane (CAM) model involving chick 
eggs, PDGF-AA, -AB, and -BB induced development of 
new blood vessels, while in another model, PDGF-BB 
but not -AA stimulated the migration of rat brain capillary 
endothelial cells.68,69 Enhanced PDGF signaling has been 
associated with tumorigenesis and angiogenesis, as well 
as other pathological events such as atherosclerosis and 
  re-stenosis of vessels after balloon angiography and coronary 
artery bypass grafting.70 In addition, PDGF inhibition may 
be a rational strategy for treatment of fibrotic liver disease, 
pulmonary fibrosis, and the development of proliferative 
vitreoretinopathy.70
The rationale for targeting the above signaling pathways 
arose from preclinical models, in which inhibition of VEGF/
VEGFR, FGF/FGFR, or PDGF/PDGFR signaling resulted 
in reduced angiogenesis and impaired tumor proliferation. 
For example, treatment with a VEGF monoclonal antibody 
inhibited the growth of tumor cell lines that had been 
injected into nude mice, but did not affect the growth rate 
of the same cell lines in vitro, supporting the explanation 
that treatment was acting against angiogenesis rather than 
directly against tumor cells.71,72 Furthermore, activation 
of PDGF and FGF pathways has been implicated in the 
development of resistance to VEGF inhibition. In a mouse 
model of pancreatic cancer, relapse after treatment with an 
anti-VEGF monoclonal antibody was associated with tumor 
revascularization secondary to hypoxia-mediated induction 
of other proangiogenic factors, including increased FGF-2 
expression.73 Upon combination treatment with both VEGF 
and FGF inhibitors, tumor revascularization and growth 
were reduced.73 Likewise, expression of PDGFR has also 
been associated with resistance to VEGF-targeted therapy 
in the mouse pancreatic cancer model, with combined tar-
geting of VEGF and PDGF signaling producing regression 
of established tumor blood vessels and inhibiting tumor 
growth.74,75 In fact, the VEGF, PDGF, and FGF signaling 
pathways appear to be highly integrated, suggesting that 
compensation and/or synergism between pathways occurs in 
angiogenesis.76,77 Thus, targeting multiple receptor tyrosine 
kinases may be required for effective   antiangiogenic 
therapies.
In the clinical development of antiangiogenic therapies, 
two approaches have been used (Table 2); the first has been to 
inhibit ligand binding and receptor activation using targeted 
antibodies, while the second has been to inhibit receptor 
activation using tyrosine kinase inhibitors targeting VEGFR, 
FGFR, and/or PDGFR. Results of Phase II and Phase III 
clinical trials of agents discussed in this review in NSCLC 
are summarized in Table 3.
Investigational antiangiogenic 
agents for NSCLC
investigational therapeutic antibodies
Ramucirumab (IMC-1121B; ImClone Systems Inc, 
New York, NY) is a human monoclonal anti-VEGFR-2 
antibody. In a Phase I study in which 37 patients with 
advanced solid malignancies were given escalating doses 
of ramucirumab, four patients (15%) had a partial response, 
and 11 patients (30%) exhibited a response or stable disease 
lasting 6 months or longer.78 The most common serious 
adverse events included hypertension (13.5%), abdominal 
pain (10.8%), anorexia, vomiting, alkaline phosphatase 
increases, headache, proteinuria, dyspnea, and deep vein 
thrombosis (each in 5.4% of patients). A dosage of 13 mg/kg 
was considered the maximum-tolerated dose in this study, OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Approved and emerging antiangiogenic therapies for NSCLC
Agent Type Target(s) Current phase of clinical   
development
Bevacizumab11 Monoclonal antibody veGF Approved for NSCLC
Ramucirumab78 Monoclonal antibody veGFR-2 Phase iii
Aflibercept111 Fusion protein veGF Phase iii
BiBF 112080 TKi veGFR-1, -2, -3, PDGFR-α/β, FGFR-1, -2, -3, Src, flt-3 Phase iii
Sorafenib87 TKi veGFR-2, -3, PDGFR-β, Raf, flt-3, c-kit Phase iii
Sunitinib92 TKi veGFR-1, -2, -3, PDGFR-α/β, c-kit, flt-3, RET Phase iii
Cediranib96 TKi veGFR-1, -2, -3, PDGFR-β, FGFR-1, c-kit Phase iii
Motesanib102 TKi veGFR-1, -2, -3, PDGFR-β, c-kit, ReT Phase iii
Pazopanib107 TKi veGFR-1, -2, -3, PDGFR-α/β, FGFR-1, -3, c-kit Phase iii
Axitinib109 TKi veGFR-1, -2, -3, PDGFR-β Phase ii
ABT-869100 TKi veGFR-1, -2, -3, PDGFR-β Phase ii
Abbreviations: c-kit, stem cell factor receptor; FGFR, fibroblast growth factor receptor; flt-3, fms-like tyrosine kinase 3; NSCLC, nonsmall cell lung cancer; PDGFR, 
platelet-derived growth factor receptor; Raf, v-raf 1 murine leukemia viral oncogene homolog 1; ReT, rearranged during transfection receptor; Src, v-src sarcoma viral 
oncogene homolog; TKi, tyrosine kinase inhibitor; veGF, vascular endothelial growth factor; veGFR, vascular endothelial growth factor receptor.
as two patients given the higher dose of 16 mg/kg experienced 
dose-limiting hypertension and deep venous thrombosis, 
respectively. Although none of the patients in this Phase I 
study had NSCLC, the findings provided the rationale for 
Phase II investigation of ramucirumab in this condition.   
A Phase II study is currently examining ramucirumab com-
bined with paclitaxel and carboplatin as a first-line treatment 
for patients with NSCLC, including those with squamous 
histology or brain metastases, with a planned enrollment 
of approximately 40 patients.79 Preliminary results from 15 
patients demonstrated an ORR of 67% (10 patients) with 
one complete response and a median PFS of 6 months. Two 
patients experienced serious adverse events (grade 2 pneu-
mothorax and grade 4 febrile neutropenia), and one additional 
patient withdrew from the study due to pneumothorax.79
investigational receptor tyrosine  
kinase inhibitors
Given the multitude of intracellular signaling pathways that 
influence tumorigenesis, a number of potential advantages 
may exist with agents that inhibit multiple targets simultane-
ously. For example, this approach may prevent the develop-
ment of resistance to antitumor agents. In addition, using a 
multitargeted approach, multiple tumorigenic pathways (such 
as angiogenesis and cell survival) may be inhibited and so 
maximize antitumor activity.
BIBF 1120 (Boehringer Ingelheim, Ingelheim,   Germany) 
is an orally available multitargeted TKI that inhibits signaling 
through VEGFR-1, -2, and -3, PDGFR-α/β, and FGFR-1, -2, 
and -3 as well as Src and flt-3.80,81 In preclinical models, 
including human tumor xenografts in nude mice and rat 
tumor models, BIBF 1120 reduced tumor vessel density and 
integrity, resulting in inhibition of tumor growth.80 In Phase 
I studies, the most common drug-related adverse events 
observed with BIBF 1120 were reversible serum liver enzyme 
elevations and mild fatigue.82–84 When BIBF 1120 was 
combined with pemetrexed, a folate antimetabolite,18 stable 
disease was achieved in 13 out of 26 patients (50%) with 
recurrent advanced NSCLC who had previously received 
one prior platinum-based chemotherapy regimen.84 In this 
study, grade 3 fatigue was reported by six patients (23%), 
and grade 3 increases in alanine transaminase (ALT) were 
observed in three patients (11%). In Phase I studies of BIBF 
1120 monotherapy in patients with advanced solid tumors, 
the first study (N = 61) observed grade 3 liver enzyme eleva-
tions in three patients receiving once-daily dosing with BIBF 
1120 and no patients receiving twice daily dosing,82 while 
the second study (N = 21) showed grade 3 elevations of ALT 
and γ-glutamyl transpeptidase (γ-GT) in six patients each 
and grade 3 elevation of aspartate aminotransferase (AST) 
in three patients.83
A Phase II trial tested BIBF 1120 monotherapy in 73 
patients with relapsed NSCLC for which one or two lines of 
chemotherapy had previously failed and who had an ECOG 
performance status of 0–2.85 Patients were assigned one of 
two doses: 150 mg (n = 37) or 250 mg (n = 36) twice daily. 
For all patients, median OS was 21.9 weeks, and median PFS 
was 6.9 weeks; one patient exhibited a partial response, and 
48% of patients exhibited stable disease. Patients with an 
ECOG performance status of 0–1 (n = 56) exhibited a median 
PFS of 11.6 weeks and a median OS of 37.7 weeks. Grade 
3 and 4 toxicities included ALT elevations (9.6%), diarrhea 
(8.2%), nausea (6.8%), γ-GT elevations (4.1%), abdomi-
nal pain (2.7%), vomiting (2.7%), anorexia (1.4%), AST OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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  elevations (1.4%), and fatigue (1.4%). Phase III trials are 
currently testing BIBF 1120 in combination with docetaxel 
in the LUME-Lung 1 study (NCT00805194) and pemetrexed 
in the LUME-Lung 2 study (NCT00806819). Of note, the 
LUME-Lung 2 study only includes patients with NSCLC of 
nonsquamous histology to conform with the FDA-approved 
indication of pemetrexed.86
Other small molecule multitargeted tyrosine kinase 
inhibitors are currently in clinical development. Sorafenib 
(Bay 43-9006; Nexavar®, Bayer, Leverkusen, Germany) 
targets tumor cell growth and angiogenesis by inhibiting sig-
naling through VEGFR-2 and -3, PDGFR-β, v-raf 1 murine 
leukemia viral oncogene homolog 1(Raf), flt-3, and stem 
cell factor receptor (c-kit).87 In a Phase II study of single-
agent sorafenib in 51 patients with relapsed or refractory 
advanced nonsquamous NSCLC, there were no responses, 
but 30 patients (59%) exhibited stable disease.88 Median 
PFS was 2.7 months, while median OS was 6.7 months. 
The most common grade 3 and 4 adverse events included 
hypertension in two patients (4%) and hand-foot skin disease 
in five patients (10%). In a larger Phase II study involving 
342 patients with pretreated NSCLC and no evidence of 
brain metastases, patients were treated with sorafenib for 
two cycles; patients who responded continued on sorafenib 
for the second stage of the study, patients with stable dis-
ease were randomized to sorafenib or placebo, and those 
with progression discontinued. Preliminary results from the 
97 patients randomized in stage 2 of the study show that 
sorafenib treatment prolonged PFS to 3.6 months compared 
with 1.9 months with placebo (P = 0.01) and resulted in stable 
disease for 16 patients (29%) compared with two patients 
with placebo (5%; P = 0.002).89 The most common grade 3 
or 4 adverse events were rash or hand-foot syndrome (15%) 
and fatigue (11%). Two patients receiving sorafenib in the 
first stage of the study and one patient in the second stage 
experienced grade $3 hemoptysis.
The Phase III ESCAPE trial evaluated sorafenib in com-
bination with carboplatin plus paclitaxel in 926 patients with 
advanced untreated nonsquamous or squamous NSCLC,90 but 
the study was halted when an interim analysis showed median 
OS was 10.7 months with sorafenib plus chemotherapy and 
10.6 months with chemotherapy alone (HR, 1.15; 95% CI, 
0.94–1.41; P = 0.915). Likewise, there was no significant 
difference between treatments in PFS (4.6 versus 5.4 months, 
respectively; HR, 0.99, 95% CI, 0.84–1.16; P = 0.433) or 
ORR (27.4% versus 24.0%; P = 0.1015). Among patients 
with squamous histology, those receiving sorafenib (n = 109) 
had a lower OS (8.9 versus 13.7 months; HR, 1.85; 95% 
CI, 1.22–2.81) and PFS (4.3 versus 5.8 months; HR, 1.31; 
95% CI, 0.94–1.83) compared with patients receiving 
chemotherapy alone (n = 114), whereas patients with other 
nonsquamous histologies had similar OS and PFS in the 
two treatment groups. The most common sorafenib-related 
grade $3 adverse events in all patients included rash (8%), 
hand-foot skin reaction (8%), and diarrhea (4%). The histo-
logical subtype of NSCLC did not appear to affect the overall 
tolerability of treatment; patients receiving sorafenib plus 
chemotherapy with nonsquamous versus squamous histolo-
gies had similar rates of drug-related adverse events occurring 
at all grades (77% versus 87%), grade 3 (26% versus 33%), 
and grade 4 (9% versus 9%), respectively. However, four out 
of six fatal hemorrhagic or bleeding events observed in this 
study (four with sorafenib and two with chemotherapy alone) 
occurred in patients with squamous histology (two in each 
arm).90 The results of the ESCAPE study led to the exclusion 
of patients with squamous histology from the subsequent 
NExUS trial, which aimed to compare first-line treatment 
with sorafenib in combination with gemcitabine and cispla-
tin versus gemcitabine and cisplatin alone in a planned 900 
patients with advanced NSCLC (NCT00449033). However, 
the NExUS trial was also halted because it did not meet the 
primary endpoint for improving OS.91
Sunitinib (SU11248; Sutent®, Pfizer; New London, CT) 
targets signaling through VEGFR-1, -2, and -3, PDGFR-α/β, 
rearranged during transfection (RET), as well as c-kit and 
flt-3.92 Sunitinib single-agent therapy was investigated in a 
Phase II trial of 63 patients with advanced NSCLC that had 
progressed after platinum-based chemotherapy.93 Patients 
were excluded from this study if they had experienced a 
grade 3 hemorrhage or hemoptysis within 4 weeks before 
the start of the treatment; additionally, patients who had 
received prior antiangiogenic therapy were excluded. Seven 
patients achieved a partial response with sunitinib, resulting 
in an ORR of 11.1% (95% CI, 4.6–21.6), while 18 patients 
(28.6%) exhibited stable disease for $8 weeks. Median 
PFS was 12 weeks (95% CI, 10.0–16.1), median OS was 
23.4 weeks (95% CI, 17.0–28.3), and the 1-year survival 
rate was 20.2% (95% CI, 10.0%–30.4%). The most com-
mon grade $3 adverse events were fatigue or asthenia in 
18 patients (29%), lymphopenia in 15 patients (25%), pain or 
myalgia in 11 patients (14%), and dyspnea in seven patients 
(11%). Another second-line Phase II study of 47 patients 
with advanced NSCLC that had been treated with at least 
two chemotherapy regimens reported a partial response in 
one patient, giving an ORR of 2.1% (95% CI, 0.1–11.3), with 
11 patients (23.4%) exhibiting stable disease for $8 weeks.94 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Median PFS and OS were 11.9 weeks (95% CI, 8.6–14.1) 
and 37.1 weeks (95% CI, 31.1–69.7), respectively, while 
the 1-year survival rate was 38.4% (95% CI, 24.2–52.5). 
Common grade $3 adverse events were fatigue or asthenia 
in eight patients (17%), neutropenia in four patients (9%), 
hypertension in four patients (9%), and dyspnea in three 
patients (6.4%). Sunitinib is currently being examined in 
a Phase II trial (CALGB 30704) as a second-line therapy 
in combination with pemetrexed (NCT00698815) and in 
a Phase III placebo-controlled trial (CALGB 30607) as a 
maintenance therapy after platinum-based chemotherapy in 
advanced NSCLC (NCT00693992).
Cediranib (AZD2171; Recentin™, AstraZeneca; 
  Wilmington, DE) inhibits signaling through VEGFR-1, -2, 
and -3, PDGFR-α/β, FGFR-1, and also has activity against 
c-kit.95,96 Cediranib was tested as a first-line therapy in com-
bination with carboplatin and paclitaxel in a randomized, 
double-blind Phase II/III trial (BR24) in 296 patients with 
advanced NSCLC.97 Patients with uncontrolled cardiovas-
cular disease, severe hypertension, or hemoptysis within 
4 weeks before treatment were excluded from this study. 
Despite initial results from the Phase II interim analysis 
suggesting higher ORR with cediranib (38%) than with 
placebo (16%, P , 0.0001), the study was halted to review 
imbalances in assigned causes of death due to toxicity of the 
30-mg dose. Median PFS was not significantly improved 
with cediranib (5.6 months) over chemotherapy alone 
(5 months; HR, 0.77; 95% CI, 0.56–1.08; P = 0.13), and a 
survival analysis update 10 months after study unblinding 
showed no significant advantage for cediranib over chemo-
therapy alone (10.5 versus 10.1 months; HR, 0.78; 95% CI, 
0.57–1.06; P = 0.11). The most common grade $3 adverse 
events with cediranib included neutropenia (49%), fatigue 
(29%), increased thyroid-stimulating hormone levels (27%), 
hypertension (19%), diarrhea (15%), and dyspnea (10%). 
A similar trial (BR29) is ongoing using a lower cediranib 
dose (20 mg) in combination with carboplatin and paclitaxel 
(NCT00795340). Another ongoing Phase II trial is currently 
evaluating cediranib in combination with pemetrexed in 
previously treated patients with NSCLC of all histological 
subtypes, with preliminary results from the first 33 enrolled 
patients showing an ORR of 16% (90% CI, 0.08–0.30) and 
grade $3 adverse events including neutropenia and fatigue, 
each of which was reported for seven patients.98
ABT-869 (Abbott; Abbott Park, IL) inhibits signaling 
through VEGFR-1, -2, and -3, and PDGFR-β,99,100 and is 
being tested in an open-label randomized Phase II trial of OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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NSCLC patients with disease progression after previous 
  treatment.101 An initial report on 24 patients receiving a 
0.10 mg/kg daily dose and 24 patients receiving a 0.25 mg/kg 
daily dose showed 33% of all patients exhibited PFS of 
16 weeks or longer. Median PFS was 109 and 108 days in 
the high- and low-dose groups, respectively. The most com-
mon grade $3 adverse events were hypertension (23% in the 
high-dose group), hand-foot syndrome (8% in the high-dose 
group), and fatigue (7% and 8% in the high- and low-dose 
groups, respectively).101
Motesanib (AMG 706; Amgen, Thousand Oaks, CA) 
inhibits signaling through VEGFR-1, -2, and -3, PDGFR-β, 
c-kit, and RET, and inhibits VEGF-induced angiogenesis 
in tumor cell xenograft models.102 Motesanib is currently 
undergoing evaluation in patients with NSCLC in combi-
nation with chemotherapy.103,104 In an initial Phase Ib study 
involving 26 patients with solid tumors, grade $3 deep vein 
thrombosis and neutropenia were reported in one patient 
each, one patient had a partial response, and seven patients 
achieved stable disease at 52 days (although none showed 
stable disease for longer than 24 weeks).104 In a subsequent 
Phase II study, 181 patients with advanced nonsquamous 
NSCLC received treatment with motesanib 125 mg once 
daily or 75 mg twice daily or bevacizumab 15 mg/kg in 
combination with carboplatin and paclitaxel.103 Preliminary 
results showed partial responses in 23% and 22% of patients 
in the 125 mg and 75 mg motesanib groups, respectively, 
and 29% in the bevacizumab group, while median PFS 
was 7.4 months (95% CI, 5.3–8.5), 5.2 months (95% CI, 
4.2–6.8), and 6.8 months (95% CI, 4.4–8.8) in the three 
treatment groups, respectively. The most common grade 
$3 adverse events in the three groups were diarrhea (19%, 
13%, and 3%), dehydration (17%, 8%, and 3%), fatigue 
(17%, 5%, and 8%), anorexia (12%, 2%, and 3%), and nau-
sea (10%, 3%, and 2%). The ongoing Phase III MONET1 
study (NCT00460317) was initially suspended because of a 
higher incidence of mortality and hemoptysis in patients with 
squamous NSCLC treated with motesanib plus carboplatin 
and paclitaxel compared with those who had nonsquamous 
NSCLC. The trial has since resumed with an expected enroll-
ment of 1400 patients, but recruitment is now limited to 
patients who have tumors with nonsquamous histology.105
Pazopanib (GW786034; GlaxoSmithKline, London, UK) 
inhibits VEGFR-1, -2, and -3, FGFR-1, PDGFR-α/β signal-
ing, and c-kit.106,107 Pazopanib as preoperative monotherapy 
was investigated in a Phase II trial involving 35 patients with 
NSCLC scheduled for resection.108 Patients with a history 
of hemoptysis or evidence of bleeding were excluded from 
the study. Of 35 patients, three had a partial response and 
30 patients (86%) showed tumor-volume reduction (two of 
whom had a volume reduction of 50% or more). The most 
common grade $3 adverse event was an increase in serum 
ALT levels, reported for two patients.
Axitinib (AG-013736; Pfizer, New London, CT) targets 
VEGFR-1, -2, -3, and PDGFR-β.109 Axitinib was evaluated in 
an open-label, single-arm Phase II study of 32 patients with 
NSCLC after at least one prior regimen of   chemotherapy.110 
Patients were excluded from this study if they had a his-
tory of grade $2 hemoptysis or brain metastases. Three 
patients demonstrated a partial response, giving an ORR of 
9%, while 10 patients (31%) experienced stable disease for 
16 weeks or longer. Median PFS was 4.9 months (95% CI, 
3.6–7.0 months), and median OS was 14.8 months (95% 
CI, 10.7–not estimable). Common grade $3 adverse events 
included fatigue in seven patients (22%), hypertension in three 
patients (9%), and hyponatremia in three patients (9%). Phase 
II clinical trials are currently evaluating first-line axitinib 
in combination with cisplatin and pemetrexed for patients 
with nonsquamous advanced NSCLC (NCT00768755) or in 
combination with cisplatin and gemcitabine in the treatment 
of advanced squamous NSCLC (NCT00735904).
Aflibercept (VEGF Trap; Regeneron, Tarrytown, NY), a 
fusion protein made up of portions of VEGFRs and human 
immunoglobulin G, has also shown activity in a Phase I clini-
cal trial of patients with advanced solid tumors.111 In a Phase 
II trial of patients with platinum-resistant, erlotinib-resistant 
adenocarcinoma of the lung, aflibercept was associated with 
an RR of 2%, median PFS of 2.7 months, and median OS 
of 6.2 months among 89 evaluable patients; the most com-
mon grade $3 adverse events included hypertension (23%), 
dyspnea (21%), and proteinuria (10%).112 A Phase III trial 
is ongoing to evaluate aflibercept as second-line therapy 
in combination with docetaxel in patients with metastatic 
NSCLC (NCT00532155).
Conclusion
Challenges associated with currently approved targeted 
therapies in NSCLC include the development of resistance 
and patient eligibility, and so there is a need for more effec-
tive therapies that improve clinical benefit with minimal 
toxicity. Ongoing studies are evaluating new antiangiogenic 
treatments, with potentially promising antitumor activity 
suggested in Phase II studies of agents that target mul-
tiple angiogenic pathways (eg, VEGFR, PDGFR, and FGF 
  pathways). However, while Phase III combination trials 
with monoclonal antibodies such as bevacizumab have been OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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promising, recently completed combination trials with TKIs 
have been disappointing. Nonetheless, results from ongoing 
studies are eagerly awaited to help determine how these 
new antiangiogenic agents may be best used either alone or 
in combination with traditional chemotherapy regimens to 
improve outcomes in individual patients.
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